Seeking research into COVID-19 in response to the Sars-CoV-2 outbreak

  • Covid-19 Innovation Challenges by Innoget
  • From United Kingdom
  • Very responsive
  • Project Size Range : Strategic project backed by large scale funding €
  • Deadline completed
    The submission process for new proposals is closed. Proposals submitted before the deadline will follow the standard evaluation process.

Desired outcome

Short-term funding of EUR 21 million (of a total funding package of EUR 23 million) will be made available in response to the current coronavirus Sars-CoV-2 outbreak via the Austrian Research Promotion Agency (FFG). The funding is provided by the Federal Ministry for Digital and Economic Affairs (BMDW) and the Federal Ministry for Climate Action, Environment, Energy, Mobility, Innovation and Technology (BMK).

The FFG will process the Emergency Call in a fast-track procedure. The planned projects should be designed for short-term implementation (development period up to 12 months). The deadline for the submission of projects is 8 April 2020 (for short-term decisions) and 11 May 2020 (for additional applications and funding decisions). The FFG warrants that the applications submitted for both deadlines will be evaluated as quickly as possible.

Covid-19 Innovation Challenges by Innoget

Details of the Innovation Need

We make every effort to process your applications as quickly as possible. Due to the large number of applications, we recommend that you first contact the FFG Funding Service, which will then direct you to the right contact persons.

Target group

The Call is aimed at Austrian companies planning a research and development project according to the Call Guideline KLIPHA-COVID19.

Companies submitting clinical trials must have preliminary results or experience with using the substance to be tested on other coronaviruses (e.g. SARS, MERS) or must have products on the market which have already demonstrated to be effective against coronaviruses in general or against symptoms similar to those caused by the SARS-CoV-2 virus (e.g. respiratory diseases).

Cooperation with science

The FFG is responsible for processing the Emergency Call and can thus not engage in match-making between companies and scientific institutions.

Given the urgency and the need for quick action we have compiled links and contact persons of scientific institutions or network organisations interested in offering their expertise and/or services to Austrian companies, which you can find on the FAQ page of the Call (German only).


Funding is provided for R&D projects and clinical trials of Austrian companies, which focus on the following topics related to the coronavirus and which can be implemented in a short period of time:

  • Virus biology and transmission;
  • Infection prevention and control;
  • Research and development of medicines and other treatments and development of new diagnostic methods;
  • Planning and conduct of clinical trials.

Competitive procedure

Given the urgency and limited budget, the Call will be conducted in a competitive procedure.

Project duration

A project duration of 12 months must be specified in applications via eCall.

Key points of the call

There will be two deadlines to enable quick decisions and allow companies to start their projects as soon as possible.

  • Deadline for submission: 8 April 2020 (16:00)
  • Deadline for submission: 11 May 2020 (16:00)
  • Deadline for funding decision: asap
  • Budget: 21 million euros
  • Funding in the form of non-repayable grants

Call documents

The following amendments were made to the Call Guideline between 10/3/2020 and 21/3/2020:

  1. clinical trials are also included,
  2. an additional second deadline of 11 May 2020 was introduced;
  3. the budget was increased from € 1 million to € 21 million;
  4. a project duration of 12 months must be specified in eCall.

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Biostatistics, Epidemiology
  • Clinical Research, Trials
  • Medical Research
  • Medical Technology / Biomedical Engineering
  • Pharmaceutical Products / Drugs
  • Virus, Virology / Antibiotics / Bacteriology
  • Medical Biomaterials
  • Human vaccines
  • Emergency Medicine Technology
  • Medical Health related
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Medical equipment
  • Welfare technologies
  • Covid-19
  • coronavirus
  • covid-19

About Covid-19 Innovation Challenges by Innoget

Ahead of the current Coronavirus outbreak, Innoget is fully committed to contributing to mobilizing scientific and expert communities to find a real solution to the Covid-19 pandemic. Therefore, we're supporting worldwide calls and programs that could help in any aspects of the coronavirus crisis.

Is your organization promoting or looking for innovation or research initiatives to mitigate the Covid-19 outbreak? Email us at to list them.

Channeled through Innoget's online open innovation network, initiatives in the health, virology, medicine, or novel technologies applied to human health, among others, are listed and disseminated to Innoget members -ranging from hospitals, research institutes, scientists, businesses, and public administrations- and innovation partners worldwide.

Covid-19 Innovation Challenges by Innoget

Never miss an update from Covid-19 Innovation Challenges by Innoget

Create your free account to connect with Covid-19 Innovation Challenges by Innoget and thousands of other innovative organizations and professionals worldwide

About Innovation Needs

Innovation Needs on Innoget are directly posted and managed by its members as well as evaluation of proposals. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.